ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY (EBMT 2026) - Mar 14, 2026 - Abstract #B111; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Eravacycline, a novel synthetic tetracycline, shares the CYP3A4 metabolic pathway with CNIs, yet comprehensive data on their potential pharmacokinetic interactions are scarce...Subgroup analysis revealed that when co-administered azoles and letermovir, no significant changes in C/D ratio were observed between pre-treatment and during treatment both in cyclosporine group (n=18) and tacrolimus group (n=7)... This study provides the first clinical evidence of pharmacokinetic interaction between eravacycline with CNIs in allo-HSCT, characterized by increased CNI exposure during eravacycline administration and delayed post-cessation exposure elevation, with this effect waning within around 2 weeks. Despite its modest magnitude, Intensified CNI monitoring and stepwise dose adjustments are recommended throughout and after eravacycline therapy, particularly for tacrolimus during eravacycline administration."
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Infectious Disease • Transplantation • CYP3A4
|
|
Jieya Luo1; Jingqi Li1; Xinhui Zheng1; Xin Chen1; Erlie Jang1
|